1. Scrip
  2. >>New Products

Neurocrine’s Ingrezza Adds Huntington’s Indication, May Have Competitive Edge

Extended-Release Rival Also Approved In 2023

 
• By Mandy Jackson

The company’s VMAT2 inhibitor joins others in the drug class with a warning about suicidal ideation, but its once-daily dosing without titration may be an advantage in chorea associated with Huntington’s disease.

Leadership concept, One leader red sphere leads other boxes
Ingrezza sales already outpace Austedo • Source: Shutterstock

Neurocrine Biosciences, Inc.’s Ingrezza (valbenazine) won its second indication in the US with approval to treat chorea associated with Huntington’s disease (HD), six years after its Food and Drug Administration approval for tardive dyskinesia. Rival VMAT2 inhibitor Austedo (deutetrabenazine) from Teva Pharmaceutical Industries Ltd. has been approved for both indications since 2017, so Neurocrine’s product is just catching up in the smaller HD chorea market, but it may capitalize on certain competitive advantages.

However, the gap between the two products may be closing in 2023, since Teva won FDA approval in February for...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from New Products

The Expanding MASH Market: How Rezdiffra, Wegovy Might Coexist

 
• By Joseph Haas

FDA approval of Novo Nordisk's Wegovy for MASH was almost as anticipated as approval of the first drug, Madrigal's Rezdiffra. Now, the MASH treatment paradigm should evolve.

Pipeline Watch: Eight Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Sanofi’s Wayrilz Gets Out Of The Blocks With First US Approval For ITP

 
• By Alexandra Shimmings

The FDA go-ahead makes it the first for a BTK inhibitor in immune thrombocytopenia. Sanofi hopes it will mark the start of a number of indications for rilzabrutinib.

Pharma Claps Back At Gonorrhea With Pipeline Progress

 
• By Alexandra Shimmings

With no advances for decades, the STI could soon be facing two new antibiotic threats, while a third novel therapy has just entered the clinic.

More from Scrip

Executives On The Move: New CEO At Mitsubishi Tanabe Pharma

Recent moves in the industry include C-suite changes at Mitsubishi Tanabe Pharma and Oculis Holding, plus clock.bio gets a new chief business officer from BioNTech.

Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia

 
• By Mandy Jackson

Approval in alpha- and beta-thalassemia by a Sept. 7 action date seemed assured, but an FDA review of proposed REMS regarding potential liver injury pushed it back to Dec. 7.

‘Attenuated’ Survival Benefit In Bemarituzumab Trial Delays Filing Plans

 
• By Alaric DeArment

Amgen and Zai Lab said the final analysis of the FORTITUDE-101 trial showed a decreased magnitude of OS benefit in first-line gastric cancer.